Aliases: SERA, PGDH, PDG.
PHGDH is human D-3-phosphoglycerate dehydrogenase (3-PGDH; EC 1.1.1.95), an NAD+-dependent oxidoreductase of the D-isomer-specific 2-hydroxyacid dehydrogenase family that assembles as a homotetramer and acts in the cytosol. It catalyzes the first and rate-limiting step of the phosphorylated pathway of de novo L-serine biosynthesis, oxidizing the glycolytic intermediate 3-phospho-D-glycerate to 3-phosphonooxypyruvate (3-phosphohydroxypyruvate) with reduction of NAD+ to NADH. Serine produced by this pathway supplies one-carbon units, nucleotides, glycine, phospholipids and redox cofactors. Human PHGDH additionally displays secondary NAD+-dependent 2-hydroxyacid dehydrogenase side-activities, most notably reduction of 2-oxoglutarate to the oncometabolite D-2-hydroxyglutarate, and in vitro malate dehydrogenase activity. Biallelic loss-of-function variants cause the serine-deficiency disorders phosphoglycerate dehydrogenase deficiency (congenital microcephaly, psychomotor retardation, seizures) and the more severe Neu-Laxova syndrome 1, while PHGDH amplification/overexpression drives serine biosynthesis in a subset of cancers. Two enzyme-independent moonlighting activities have additionally been reported in Alzheimer's-disease models: a nuclear, chromatin-associated transcriptional-regulator role acting through a predicted DNA-binding helix-helix-turn-helix subdomain, and, separately, an RNA-binding activity that binds the EIF2AK1 3'UTR and promotes BACE1 translation. Both are stated to be independent of catalysis, the second also independent of the first; both come from a single laboratory and neither has been independently replicated.
Relationship is the entry's genetic[].relationship_type. untyped means the entry has a genetic record for the gene but does not type it; its free-text association is shown instead.
| Disorder | Relationship | Where the gene appears |
|---|---|---|
| 3-Phosphoglycerate Dehydrogenase Deficiency | causative germline |
mechanism: PHGDH Enzyme Deficiency
subtype: Adult; Infantile; Juvenile; Neu-Laxova
|
| Ewing Sarcoma | no genetic record |
mechanism: ATF4-Serine-Glycine Metabolic Reprogramming
|
| INPP5K-Related Congenital Muscular Dystrophy | no genetic record |
mechanism: PHGDH Dysregulation
|
An entry matches when ClinGen's MONDO disease is the entry's own disease term, a subtype term, or an exact-match mapping. An amber status marks an entry ClinGen supports the gene for (Definitive, Strong or Moderate) whose own record does not type it. A Limited, Disputed or Refuted tier on such an entry is not a gap.
| ClinGen disease | MOI | Classification | dismech entry |
|---|---|---|---|
| neurometabolic disorder due to serine deficiency MONDO:0018162 | AR | Definitive 2020-06-29 |
no dismech entry |
Identity from HGNC (snapshot 2026-10-01). Page layers are described in the gene pages documentation.